Pure Global AI
NCT06388720Recruiting

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

A Study to Assess the Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy in Patients With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to BCG Therapy
National Cancer Center, KoreaPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Bladder Cancer
Drug/Device/Intervention
Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
National Cancer Center, Korea
Location
Goyang-si, South Korea
Timeline & enrollment
Phase
Phase 2
Start date
Apr 30, 2024
End date
Dec 31, 2027
Enrollment
82 participants
Primary outcome

Recurrent free survival in sequential treatment group.

Summary

The aim of this study is to evaluate the effectiveness and safety of mitomycin-c and
 gemcitabine sequential instillation in BCG unresponsive high risk non-muscle invasive bladder
 cancer patients.

ICD-10 classifications
Malignant neoplasm of bladderMalignant neoplasm: Bladder, unspecifiedMalignant neoplasm: Dome of bladderMalignant neoplasm: Overlapping lesion of bladderMalignant neoplasm: Lateral wall of bladder
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06388720
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06388720 through Pure Global AI's free database. This Phase 2 trial is sponsored by National Cancer Center, Korea and is currently Recruiting. The study focuses on Bladder Cancer. Target enrollment is 82 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.